DiscoverRaising HealthAdapting Biopharma to AI: A 2024 Update with Greg Meyers
Adapting Biopharma to AI: A 2024 Update with Greg Meyers

Adapting Biopharma to AI: A 2024 Update with Greg Meyers

Update: 2024-08-27
Share

Description

Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb, or BMS, joins Jorge Conde, general partner at a16z.

This is a follow-up to their 2023 episode, where they discussed how biopharma can adapt to AI. Now, they revisit the conversation to see what’s changed and what hasn’t.

Together, they chat through tech as a competitive differentiator for large companies, generative AI for drug development, and what Greg and BMS look for in potential partners. They also highlight the importance of being agile and adaptable while navigating the changing landscape of biotech, providing valuable insights for founders.

Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Adapting Biopharma to AI: A 2024 Update with Greg Meyers

Adapting Biopharma to AI: A 2024 Update with Greg Meyers

Jorge Conde, Greg Meyers, Kris Tatiossian, Olivia Webb